PE59399A1 - Compuestos heterociclicos, composiciones farmaceuticas que los comprenden y metodos para inhibir la liberacion del peptido � - amiloide y/o su sintesis mediante el uso de dichos compuestos - Google Patents
Compuestos heterociclicos, composiciones farmaceuticas que los comprenden y metodos para inhibir la liberacion del peptido � - amiloide y/o su sintesis mediante el uso de dichos compuestosInfo
- Publication number
- PE59399A1 PE59399A1 PE1998000144A PE00014498A PE59399A1 PE 59399 A1 PE59399 A1 PE 59399A1 PE 1998000144 A PE1998000144 A PE 1998000144A PE 00014498 A PE00014498 A PE 00014498A PE 59399 A1 PE59399 A1 PE 59399A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- alkynyl
- formula
- optionally substituted
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/10—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA A-B-C; A ES A(i), R1 ES ALQUILO, ALQUENILO, ALQUINILO, OPCIONALMENTE SUSTITUIDOS, ENTRE OTROS; Z ES a)UN GRUPO DE FORMULA -CX`X''-CO-, X', X'' SON H, OH, F o FORMAN UN GRUPO OXO; b)UN GRUPO DE FORMULA -T-CX'X''-CO-; T ES O, S, NR3; R3 ES H, ACILO, ALQUILO, ENTRE OTROS; c)UN GRUPO DE FORMULA CX'X''T(CO), R2 ES ALQUILO, ALQUENILO, ALQUINILO OPCIONALMENTE SUSTITUIDOS, ENTRE OTROS; R6 ES ALQUILO, ALQUENILO, ALQUINILO OPCIONALMENTE SUSTITUIDOS, m Y p SON 0-1; Aii) R1 ES ALQUILO, ALQUENILO, ALQUINILO, ENTRE OTROS; T' ES UN ENLACE, O, S, NR3; W, X SON (CR7R7)q, O, S, NR8, q ES 1-2; R7 Y R8 SON H, ALQUILO, CICLOALQUILO, ENTRE OTROS; R4 ES H, ALQUILO, ALQUENILO, OPCIONALMENTE SUSTITUIDOS, ENTRE OTROS; B ES -CO-NH-CR5; R5 ES ALQUILO, ALQUENILO, ALQUINILO, OPCIONALMENTE SUSTITUIDOS; B(ii); B(iii); B(iv), SI A ES LA FORMULA A(ii) O A(iii), B PUEDE SER UN ENLACE. C ES -C(O)Y o -C(S)Y, Y ES ALQUILO o CICLOALQUILO, NHSO2R8, ENTRE OTROS; C(ii) CR11R11Y', R11 ES H, ALQUILO, CICLOALQUILO OPCIONALMENTE SUSTITUIDO, ENTRE OTROS; Y' ES OH, ALCOXI, AMINO, ENTRE OTROS; C(iii) OPCIONALMENTE FUSIONADO. UN COMPUESTO PREFERIDO ES (S)-2-[1-(3,5-DIFLUORFENILACETAMIDO)ETIL]-4-METOXICARBONIL-4-FENILMETIL-2-IMIDAZOLINA; ENTRE OTROS. PUEDE PREVENIR EL INICIO O TRATAR LA ENFERMEDAD DE ALZHEIMER (AD)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80826397A | 1997-02-28 | 1997-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE59399A1 true PE59399A1 (es) | 1999-06-21 |
Family
ID=25198310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1998000144A PE59399A1 (es) | 1997-02-28 | 1998-02-27 | Compuestos heterociclicos, composiciones farmaceuticas que los comprenden y metodos para inhibir la liberacion del peptido � - amiloide y/o su sintesis mediante el uso de dichos compuestos |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0968198A1 (es) |
| JP (1) | JP2001513107A (es) |
| KR (1) | KR20000075767A (es) |
| CN (1) | CN1253554A (es) |
| AR (1) | AR011164A1 (es) |
| AU (1) | AU6662298A (es) |
| BR (1) | BR9807876A (es) |
| CA (1) | CA2278674A1 (es) |
| CO (1) | CO4920244A1 (es) |
| EA (1) | EA199900778A1 (es) |
| HR (1) | HRP980093A2 (es) |
| HU (1) | HUP0001293A3 (es) |
| ID (1) | ID22873A (es) |
| IL (1) | IL130851A0 (es) |
| NO (1) | NO994016L (es) |
| NZ (1) | NZ336613A (es) |
| PE (1) | PE59399A1 (es) |
| PL (1) | PL335424A1 (es) |
| TR (1) | TR199902071T2 (es) |
| WO (1) | WO1998038177A1 (es) |
| YU (1) | YU7998A (es) |
| ZA (1) | ZA981627B (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6635632B1 (en) | 1996-12-23 | 2003-10-21 | Athena Neurosciences, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| KR20010033408A (ko) * | 1997-12-22 | 2001-04-25 | 진 엠. 듀발 | 폴리시클릭 α-아미노-ε-카프롤락탐 및 관련 화합물 |
| US6774125B2 (en) | 1998-06-22 | 2004-08-10 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| US6552013B1 (en) | 1998-06-22 | 2003-04-22 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| AU4707999A (en) * | 1998-06-22 | 2000-01-10 | Elan Pharmaceuticals, Inc. | Compounds for inhibiting beta-amyloid peptide release and/or its synthesis |
| US6569851B1 (en) | 1998-06-22 | 2003-05-27 | Elan Pharmaceutials, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| US6509331B1 (en) | 1998-06-22 | 2003-01-21 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| US6528505B1 (en) | 1998-06-22 | 2003-03-04 | Elan Pharmaceuticals, Inc. | Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| US6737038B1 (en) | 1998-11-12 | 2004-05-18 | Bristol-Myers Squibb Company | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging |
| US6395897B1 (en) | 1999-03-02 | 2002-05-28 | Boehringer Ingelheim Pharmaceuticals, Inc. | Nitrile compounds useful as reversible inhibitors of #9 cathepsin 5 |
| US7160880B1 (en) * | 1999-05-14 | 2007-01-09 | Cenes Limited | Short-acting benzodiazepines |
| GB9911803D0 (en) * | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| EP1210338A2 (en) * | 1999-08-05 | 2002-06-05 | IGT Pharma Inc. | 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system |
| US6420364B1 (en) | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
| WO2001087354A2 (en) | 2000-05-17 | 2001-11-22 | Bristol-Myers Squibb Pharma Company | Use of small molecule radioligands for diagnostic imaging |
| BR0106717A (pt) | 2000-06-01 | 2002-04-16 | Bristol Myers Squibb Pharma Co | Compostos, composição farmacêutica e usos dos compostos de lactama inovadora |
| DE10029077A1 (de) * | 2000-06-13 | 2001-12-20 | Bayer Ag | Thiazolylsubstituierte Heterocyclen |
| US6432944B1 (en) | 2000-07-06 | 2002-08-13 | Bristol-Myers Squibb Company | Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives |
| FR2840899B1 (fr) * | 2002-06-12 | 2005-02-25 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique |
| AR039059A1 (es) | 2001-08-06 | 2005-02-09 | Sanofi Aventis | Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios |
| EP1550725A4 (en) | 2002-06-05 | 2010-08-25 | Kaneka Corp | PROCESS FOR PRODUCING OPTICALLY ACTIVE alpha-METHYLCYSTEINE DERIVATIVE |
| NZ584773A (en) | 2004-09-17 | 2012-07-27 | Whitehead Biomedical Inst | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity |
| US7449486B2 (en) | 2004-10-19 | 2008-11-11 | Array Biopharma Inc. | Mitotic kinesin inhibitors and methods of use thereof |
| UA95907C2 (en) | 2005-05-02 | 2011-09-26 | Эррей Биофарма Инк. | Mitotic kinesin inhibitors and methods of use thereof |
| EP1757290A1 (en) | 2005-08-16 | 2007-02-28 | Zentaris GmbH | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors |
| WO2008042928A2 (en) | 2006-10-03 | 2008-04-10 | Array Biopharma, Inc. | Oxadiazole and thiadiazole derivatives as mitotic kinesin inhibitors and methods of use thereof |
| ES2700613T3 (es) * | 2008-07-16 | 2019-02-18 | Bitop Ag | Síntesis de amidinas cíclicas |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| EP2431035A1 (en) | 2010-09-16 | 2012-03-21 | Æterna Zentaris GmbH | Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| US8809372B2 (en) | 2011-09-30 | 2014-08-19 | Asana Biosciences, Llc | Pyridine derivatives |
| CN103435549A (zh) * | 2013-08-14 | 2013-12-11 | 无锡惠飞生物医药技术有限公司 | 5-甲基-7-氨基-5H,7H-二苯并[b,d]氮杂环庚-6-酮的制备方法 |
| CN105646208B (zh) * | 2016-02-24 | 2018-10-16 | 潍坊晶润化工股份有限公司 | 丙酮酸甲酯的制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11506923A (ja) * | 1995-06-06 | 1999-06-22 | アセナ ニューロサイエンシーズ，インコーポレイテッド | 新しいカテプシンならびにその阻害のための方法および組成物 |
-
1998
- 1998-02-24 AR ARP980100812A patent/AR011164A1/es unknown
- 1998-02-24 HR HR08/808,236A patent/HRP980093A2/hr not_active Application Discontinuation
- 1998-02-26 ZA ZA9801627A patent/ZA981627B/xx unknown
- 1998-02-27 AU AU66622/98A patent/AU6662298A/en not_active Abandoned
- 1998-02-27 CO CO98010854A patent/CO4920244A1/es unknown
- 1998-02-27 JP JP53773298A patent/JP2001513107A/ja active Pending
- 1998-02-27 WO PCT/US1998/003373 patent/WO1998038177A1/en not_active Application Discontinuation
- 1998-02-27 NZ NZ336613A patent/NZ336613A/en unknown
- 1998-02-27 PE PE1998000144A patent/PE59399A1/es not_active Application Discontinuation
- 1998-02-27 IL IL13085198A patent/IL130851A0/xx unknown
- 1998-02-27 ID IDW990811A patent/ID22873A/id unknown
- 1998-02-27 PL PL98335424A patent/PL335424A1/xx unknown
- 1998-02-27 KR KR1019997007839A patent/KR20000075767A/ko not_active Application Discontinuation
- 1998-02-27 EP EP98908637A patent/EP0968198A1/en not_active Withdrawn
- 1998-02-27 BR BR9807876-3A patent/BR9807876A/pt not_active IP Right Cessation
- 1998-02-27 EA EA199900778A patent/EA199900778A1/ru unknown
- 1998-02-27 CN CN98802875A patent/CN1253554A/zh active Pending
- 1998-02-27 HU HU0001293A patent/HUP0001293A3/hu unknown
- 1998-02-27 YU YU7998A patent/YU7998A/sh unknown
- 1998-02-27 TR TR1999/02071T patent/TR199902071T2/xx unknown
- 1998-02-27 CA CA002278674A patent/CA2278674A1/en not_active Abandoned
-
1999
- 1999-08-19 NO NO994016A patent/NO994016L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2278674A1 (en) | 1998-09-03 |
| YU7998A (sh) | 2002-06-19 |
| ZA981627B (en) | 1999-10-05 |
| KR20000075767A (ko) | 2000-12-26 |
| WO1998038177A1 (en) | 1998-09-03 |
| CO4920244A1 (es) | 2000-05-29 |
| CN1253554A (zh) | 2000-05-17 |
| NO994016D0 (no) | 1999-08-19 |
| EP0968198A1 (en) | 2000-01-05 |
| HUP0001293A3 (en) | 2000-09-28 |
| JP2001513107A (ja) | 2001-08-28 |
| IL130851A0 (en) | 2001-01-28 |
| NO994016L (no) | 1999-10-18 |
| ID22873A (id) | 1999-12-16 |
| PL335424A1 (en) | 2000-04-25 |
| HRP980093A2 (en) | 1998-12-31 |
| HUP0001293A1 (hu) | 2000-08-28 |
| BR9807876A (pt) | 2000-02-29 |
| AR011164A1 (es) | 2000-08-02 |
| AU6662298A (en) | 1998-09-18 |
| NZ336613A (en) | 2001-10-26 |
| TR199902071T2 (xx) | 2000-01-21 |
| EA199900778A1 (ru) | 2000-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE59399A1 (es) | Compuestos heterociclicos, composiciones farmaceuticas que los comprenden y metodos para inhibir la liberacion del peptido � - amiloide y/o su sintesis mediante el uso de dichos compuestos | |
| AR029216A1 (es) | Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento | |
| PE108898A1 (es) | Derivados 6,5-heterobiciclicos sustituidos | |
| CL2003002756A1 (es) | Compuestos derivados de (1-carbamoil-1,1-defenilmetil)-1-[substituido)alquil]purrolidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del sindrome de intestino irritable o incontinencia. | |
| ES2162676T3 (es) | Derivados de fenileno sustituidos en meta y su uso como antagonistas o inhibidores de integrina alfav,beta3. | |
| ATE188472T1 (de) | 4-arylmethyloxymethyl piperidine als tachykinin antagonisten | |
| ES2256969T3 (es) | Compuestos de benzotiazol inhibidores de proteina tirosina qauinasa. | |
| ATE204269T1 (de) | Substituierte biphenyl- oder phenylpyridinderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen | |
| DE69133277D1 (de) | Chelat-zubereitungen, die oximverbindungen enthalten | |
| ATE228115T1 (de) | Bizyklische fibrinogenantagonisten | |
| DE60043349D1 (de) | Chinazolin-derivate und ihre verwendung als arzneimittel | |
| DE69622031D1 (de) | INDOLDERIVATE ALS cGMP-PDE INHIBITOREN | |
| AR025352A1 (es) | Compuesto inhibidor de la proteasa del hiv, su uso para preparar medicamentos, composiciones que lo comprenden, procedimientos e intermediarios paraprepararlos y procedimiento para preparar los intermediarios | |
| AR035153A1 (es) | Derivados de carboxamidas y cetonas de dihidrobenzodioxina | |
| DE69132363D1 (de) | Chelat-zubereitung, die alpha-diamin-verbindungen enthalten | |
| AR002690A1 (es) | Derivado de bencimidazol o sales del mismo, composicion farmaceutica, agente inmunosupresor y agente antiinflamatorio que lo contienen yprocedimientos para preparar dicho derivado. | |
| SE9604341D0 (sv) | Hepta-peptide oxytocin analogue | |
| NO940737D0 (no) | Antidepressive midler | |
| PA8495101A1 (es) | Derivados de 13-metileritromicina | |
| AR002012A1 (es) | Un compuesto, una composicion farmaceutica que lo comprende, su uso, metodo de tratamiento terapeutico, metodo para la preparacion del compuesto. | |
| DE69522945D1 (de) | Verbindungen, die als antiproliferative mittel und als garft inhibitoren verwendbar sind | |
| AR012489A1 (es) | Tiofenopiridinas antagonistas del factor de liberacion de corticotropina. procedimiento para su preparacion, el uso de las mismas en la preparacionde un medicamento, composicion farmaceutica que las comprende, procedimiento para la preparacion de dicha composicion, un compuesto intermediario y | |
| CO5631434A2 (es) | Derivados de piridina-carboxamida y su uso como plaguicidas | |
| ATE86602T1 (de) | Alpha,alpha disubstituierte n-cycloalkylalkylbenzylamine, verfahren zu ihrer herstellung, ihre anwendung als arzneimittel und ihre zwischenprodukte bei der herstellung. | |
| AR007108A1 (es) | Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |